Challenges in Treating Metastatic Urothelial Cancer: A Geriatric Perspective
Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.
EP: 1.Patient Case: A 73-Year-Old Man With Metastatic Urothelial Carcinoma
EP: 2.Challenges in Treating Metastatic Urothelial Cancer: A Geriatric Perspective
EP: 3.Biomarker Testing in Urothelial Cancer: Implications for Treatment Decisions
EP: 4.Early Mutation Profiling in Urothelial Cancer: A Path to Targeted Therapy
EP: 5.Frontline Options for Metastatic Urothelial Cancer: Tailoring Treatment Choices
EP: 6.Second-Line Strategies in Metastatic Urothelial Cancer: Balancing Options and Risks
EP: 7.Navigating Neuropathy in Urothelial Cancer Treatment
EP: 8.Future Directions in Urothelial Cancer Treatment: Clinical Trials and Novel Agents
Case: A 73-Year-Old Man with Metastatic Urothelial Carcinoma
Initial Clinical Presentation:
- A 73-year-old man presented to you from their local urologist with dizziness and hematuria
- PMH: hypertension and diabetes (uncontrolled)
- SH: former smoker; consumes alcohol 2-3 times per week
- Chest x-ray and CT revealed a 3.7-cm mass on the right lateral wall of the bladder and liver metastases
- Cystoscopic biopsy/pathology confirmed stage IV urothelial carcinoma
- ECOG PS 1
- CrCl 65 mL/min
- The patient received gemcitabine + cisplatin (6 cycles)
- Partial response at completion of chemotherapy
- No maintenance therapy given, although discussed with patient
Current Clinical Presentation:
- 7 months later, disease progression was discovered on routine follow up imaging
Treatment:
- The patient received pembrolizumab and a partial response was achieved at 6 cycles
- Molecular testing showed no FGFR2 mutation or fusion
FDA Oks FoundationOne CDx and Liquid CDx for Use With Olaparib/Abiraterone in Prostate Cancer
September 4th 2024The FDA has approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to be used with olaparib, abiraterone, and prednisone or prednisolone BRCA-mutated metastatic castration-resistant prostate cancer.
Read More
Lenvatinib Gets Updated Label to Include First-Line Efficacy in Advanced nccRCC
August 20th 2024The US label for lenvatinib has been updated to include new clinical efficacy data for its use as a first-line treatment in advanced non-clear cell renal cell carcinoma, based on results from the KEYNOTE-B61 trial.
Read More
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Darolutamide Plus ADT Shows Promise in Treating Metastatic Prostate Cancer
July 17th 2024Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Read More
